3D Echocardiography and Cardiovascular Prognosis in Mitral Regurgitation

Haukeland University Hospital300 enrolled

Overview

The 3D-PRIME study will analyse whether use of 3D echocardiography can improve risk stratification and cardiovascular outcome in patients with mitral regurgitation of different etiologies.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Mitral Regurgitation

Interventions

Use of 3D echocardiography in patient follow-upDIAGNOSTIC_TEST

Patients will undergo clinical and echocardiographic examination including detailed 3D echocardiography at study inclusion and at least one follow-up visit.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients with primary or secondary mitral regurgitation (MR) * MR of moderate or severe degree * 3D echocardiographic examinations of \>= good spatial and temporal resolution Exclusion Criteria: * Co-existence of another valve disease of severe degree * Inability to give informed consent

Locations (1)

Haukeland University Hospital

Bergen, Norway

RECRUITING

Outcomes

Primary Outcomes

Major cardiovascular event

Death, mitral valve intervention, heart failure hospitalization

Time frame: 24 months

Secondary Outcomes

All-cause death

Time frame: 24 months

Cardiovascular death

Time frame: 24 months

Mitral valve intervention

Time frame: 24 months

Central Contacts

Dana Cramariuc, MD PhD

CONTACT

+4755976755 cdan@helse-bergen.no

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.